MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas

A. J M Ferreri, S. Dell'Oro, M. Foppoli, M. Bernardi, A. A. Brandes, A. Tosoni, M. Montanari, M. Balzarotti, M. Spina, F. Ilariucci, F. Zaja, C. Stelitano, F. Bobbio, G. Corazzelli, L. Baldini, M. Ponzoni, P. Picozzi, F. Caligaris Cappio, M. Reni

Research output: Contribution to journalArticlepeer-review

Abstract

The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 ± 7%) was obtained.

Original languageEnglish
Pages (from-to)1435-1438
Number of pages4
JournalNeurology
Volume66
Issue number9
DOIs
Publication statusPublished - May 2006

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint

Dive into the research topics of 'MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas'. Together they form a unique fingerprint.

Cite this